The burgeoning landscape of novel treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a https://estellenzcf856274.wikinarration.com/7337903/retatrutide_vs_tirzepatide_a_comparative_analysis